640 M. Guzmán
Guzmán M (2003) Cannabinoids: potential anticancer agents. Nat Rev Cancer 3:745–755
Guzmán M, Galve-Roperh I, Sánchez C (2001) Ceramide: a new second messenger of
cannabinoid action. Trends Pharmacol Sci 22:19–22
Hampson AJ, Grimaldi M (2001) Cannabinoid receptor activation and elevated cyclic AMP
reduce glutamate neurotoxicity. Eur J Neurosci 13:1529–1536
Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998) Cannabidiol and∆9-tetrahydro-
cannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 95:8268–8273
Hansen HH, Schmid PC, Bittigau P, Lastres-Becker I, Berrendero F, Manzanares J, Ikono-
midou C, Schmid HH, Fernández-Ruiz JJ, Hansen HS (2001) Anandamide, but not
2-arachydonoylglycerol, accumulates during in vivo neurodegeneration. J Neurochem
78:1415–1427
Howlett AC (1984) Inhibition of neuroblastoma adenylate cyclase by cannabinoid and
nantradol compounds. Life Sci 35:1803–1810
Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham
M, Mackie K, Martin BR, Mechoulam R, Pertwee RG (2002) International Union of
Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161–
202
Jones S, Howl J (2003) Cannabinoid receptor systems: therapeutic targets for tumour inter-
vention. Expert Opin Ther Targets 7:749–758
Kaminski NE (1998) Regulation of the cAMP cascade, gene expression and immune function
by cannabinoid receptors. J Neuroimmunol 83:124–132
Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, Friedman H (2003) The cannabinoid
system and immune modulation. J Leukoc Biol 74:486–496
Knoller N, Levi L, Shoshan I, Reichenthal E, Razon N, Rappaport ZH, Biegon A (2002)
Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized,
placebo-controlled, phase II clinical trial. Crit Care Med 30:548–554
Lastres-Becker I, De Miguel R, Fernández-Ruiz JJ (2003) The endocannabinoid system and
Huntington’s disease. Curr Drug Target CNS Neurol Disord 2:335–347
Liu J, Gao B, Mirshahi F, Sanyal AJ, Khanolkar AD, Makriyanis A, Kunos G (2000) Functional
CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J 346:835–840
Maccarrone M, Finazzi-Agro A (2003) The endocannabinoid system, anandamide and the
regulation of mammalian cell apoptosis. Cell Death Differ 10:946–955
Marsicano G, Moosmann B, Hermann H, Lutz B, Behl C (2002) Neuroprotective proper-
ties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1.
J Neurochem 80:448–456
Marsicano G, Goodenough S, Monory K, Hermann H, Eder M, Cannich A, Azad SC, Cas-
cio MG, Gutiérrez SO, van der Stelt M, López-Rodríguez ML, Casanova E, Schutz G,
Zieglgansberger W, Di Marzo V, Behl C, Lutz B (2003) CB1 cannabinoid receptors and
on-demand defense against excitotoxicity. Science 302:84–88
Massi P, Vaccani A, Ceruti S, Colombo A, Abbracchio MP, Parolaro D (2004) Antitumor
effects of cannabidiol, a non-psychotropic cannabinoid, on human glioma cell lines.
J Pharmacol Exp Ther 308:838–845
Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a cannabi-
noid receptor and functional expression of the cloned cDNA. Nature 346:561–564
McKallip RJ, Lombard C, Fisher M, Martin BR, Ryu S, Grant S, Nagarkatti PS, Nagarkatti
M (2002a) Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant
lymphoblastic disease. Blood 100:627–634
McKallip RJ, Lombard C, Martin BR, Nagarkatti M, Nagarkatti PS (2002b)∆9-TetraHydro-
Cannabinol-induced apoptosis in the thymus and spleen as a mechanism of immuno-
suppression in vitro and in vivo. J Pharmacol Exp Ther 302:451–465
Mechoulam R, Spatz M, Shohami E (2002) Endocannabinoids and neuroprotection. Sci
STKE 129:RE5
Melck D, Rueda D, Galve-Roperh I, De Petrocellis L, Guzmán M, Di Marzo V (1999) Involve-
ment of the cAMP/protein kinase pathway and of mitogen-activated protein kinase in